---
title: "Afamelanotide"
canonical_url: https://peptidelibrary.app/library/afamelanotide
description: "FDA-approved α-MSH analog implant (SCENESSE) to increase pain-free light exposure in adults with erythropoietic protoporphyria."
updated: 2026-09-06
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Afamelanotide

Afamelanotide (also called SCENESSE or Melanotan I) is an FDA-approved α-MSH analog in the MC1R Agonist class. Afamelanotide is a synthetic analog of alpha-melanocyte-stimulating hormone with two substitutions, norleucine at position 4 and D-phenylalanine at position 7, which greatly increase potency and resistance to degradation relative to native alpha-MSH.

FDA-approved α-MSH analog implant (SCENESSE) to increase pain-free light exposure in adults with erythropoietic protoporphyria.

Also known as: SCENESSE, Melanotan I, NDP-MSH, CUV1647, Melanotan 1.

Categories: Cosmetic.

## Classification

- Type: FDA-approved α-MSH analog
- Mechanism class: MC1R Agonist
- Development stage: Approved product
- Regulatory class: FDA-approved medicine

## Mechanism

Afamelanotide is a synthetic analog of alpha-melanocyte-stimulating hormone with two substitutions, norleucine at position 4 and D-phenylalanine at position 7, which greatly increase potency and resistance to degradation relative to native alpha-MSH. It is a potent agonist at the melanocortin-1 receptor on melanocytes, where Gs-coupled signalling raises cyclic AMP and induces microphthalmia-associated transcription factor, driving eumelanin synthesis. Because this occurs downstream of the receptor it does not require ultraviolet exposure to initiate pigmentation. In erythropoietic protoporphyria the resulting increase in eumelanin absorbs and scatters visible light, which is the wavelength range that provokes phototoxicity in that condition.

Targets: MC1R, Melanocytes.

Origin: Synthetic [Nle4, D-Phe7]-α-MSH.

## Properties

- Sequence: Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val
- Molecular formula: C78H111N21O19
- Molecular weight: 1,646.9 g/mol
- CAS number: 75921-69-6
- Half-life: ~30 minutes (plasma); ~15 h (from implant)
- Studied routes: Subcutaneous

## Evidence

- Evidence level: FDA Approved
- Highest documented: Regulatory review (FDA label)
- Human trials: 3
- Controlled human trials: 2
- Preclinical sources: 0

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. SCENESSE (afamelanotide) implant - FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Adults with a history of phototoxic reactions from erythropoietic protoporphyria. Increase in pain-free light exposure [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48)
2. NCT01605136 - Phase III Confirmatory Study in Erythropoietic Protoporphyria. Controlled human trial. Population: Patients with erythropoietic protoporphyria (n=93). Pain-free sunlight exposure [Source](https://clinicaltrials.gov/study/NCT01605136)
3. NCT04053270 - Multicentre Phase III Erythropoietic Protoporphyria Study. Controlled human trial. Population: Patients with erythropoietic protoporphyria (n=100). Light tolerance and quality of life [Source](https://clinicaltrials.gov/study/NCT04053270)
4. NCT04525157 - Afamelanotide and Narrow-Band Ultraviolet B Phototherapy in Vitiligo. Human study (early or uncontrolled). Population: Patients with vitiligo (n=21). Repigmentation alongside narrow-band UVB phototherapy [Source](https://clinicaltrials.gov/study/NCT04525157)

### Registered trials

- [NCT01605136](https://clinicaltrials.gov/study/NCT01605136)
- [NCT04053270](https://clinicaltrials.gov/study/NCT04053270)
- [NCT04525157](https://clinicaltrials.gov/study/NCT04525157)

## Safety

Side effects: Nausea; Implant-site reactions; Headache; Hyperpigmentation.

Risks: Prescription implant only; Not approved as a tanning agent.

Human safety basis: FDA prescribing information

## Regulatory status

Afamelanotide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

- FDA status: Approved
- WADA status: Permitted
- Availability: Prescription-Only

## Frequently asked questions

### What is Afamelanotide?

FDA-approved α-MSH analog implant (SCENESSE) to increase pain-free light exposure in adults with erythropoietic protoporphyria.

### How does Afamelanotide work?

Afamelanotide is a synthetic analog of alpha-melanocyte-stimulating hormone with two substitutions, norleucine at position 4 and D-phenylalanine at position 7, which greatly increase potency and resistance to degradation relative to native alpha-MSH. It is a potent agonist at the melanocortin-1 receptor on melanocytes, where Gs-coupled signalling raises cyclic AMP and induces microphthalmia-associated transcription factor, driving eumelanin synthesis.

### Is Afamelanotide FDA approved?

Yes. Afamelanotide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

### What is the half-life of Afamelanotide?

Reported half-life for Afamelanotide is ~30 minutes (plasma); ~15 h (from implant). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of Afamelanotide?

Afamelanotide has the sequence Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val, giving a chain of 13 amino acids. Its molecular formula is C78H111N21O19.

### Is Afamelanotide banned in sport?

Afamelanotide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

## References

- [FDA label — SCENESSE](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf)
- [Afamelanotide for Erythropoietic Protoporphyria — N Engl J Med, 2015](https://pubmed.ncbi.nlm.nih.gov/26132941/)
- [Afamelanotide in protoporphyria and other skin diseases: a review — Postepy Dermatol Alergol, 2024](https://pubmed.ncbi.nlm.nih.gov/38784937/)
- [Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications — J Drugs Dermatol, 2021](https://pubmed.ncbi.nlm.nih.gov/33683075/)
- [Afamelanotide: A Review in Erythropoietic Protoporphyria — Am J Clin Dermatol, 2016](https://pubmed.ncbi.nlm.nih.gov/26979527/)
- [Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria — Expert Rev Clin Pharmacol, 2015](https://pubmed.ncbi.nlm.nih.gov/25470471/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
